

# Endoscopic lavage after intraventricular haemorrhage in neonates in the UK: a national randomised controlled trial on the efficacy of neuro-endoscopic lavage

<b>Submission date</b> 15/11/2023	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 21/12/2023	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 04/11/2025	<b>Condition category</b> Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Around one in thirteen infants is born preterm in the United Kingdom. Despite major advances in survival, intraventricular haemorrhage (IVH) remains one of the most serious complications of preterm birth. Intraventricular haemorrhage (IVH) is bleeding into the fluid spaces of the brain with severe Intraventricular Haemorrhage (IVH) and Post-haemorrhagic Ventricular Dilatation (PHVD) and is common in babies who are born premature. This results in a build-up of brain fluid, that may increase the pressure in the brain. Bleeding in the brain can cause a risk to life and also cause problems with vision, hearing, cognition (understanding) and motor function (movement). The current best treatment available involves implanting a temporary drainage device in a short operation. There is a new treatment called neuroendoscopic lavage (NEL), which involves the insertion of a small camera into the fluid spaces (ventricles) of the brain to wash out as much of the blood as possible before inserting the temporary drainage tube. This study will investigate whether the addition of NEL to the standard procedure of inserting a temporary cerebrospinal fluid (CSF) drainage device will improve children's development at 2 years of age

### Who can participate?

Premature infants born before 37 weeks of gestational age with severe IVH and PHVD

### What does the study involve?

Eligible participants will be randomly allocated into one of two groups:

1. Intervention group: neuroendoscopic lavage, or washout, and temporary drainage device.
2. Control group: continue with usual care.

After the operation all participants will be cared for in the usual way. Participants from both groups will undergo follow ups which will include regular neurosurgical and paediatric check-ups over a 2-year period. During study visits the participant's parent/guardian(s) will be asked to complete questionnaires to collect information about their views of the participant's development. They will also be asked about the participants' and their own quality of life. At about 2 years of age, participants will also be required to attend an additional visit where they

will undergo specific assessments to see how well the participant is developing. This assessment will be done by a qualified healthcare professional with experience at performing developmental assessments for children and who does not know which group the participant is in.

What are the possible benefits and risks of participating?

The information from the trial will help to improve treatment for future patients with IVH.

All medical procedures involve the risk of harm, but this is usually low. The risks of taking part in the study are mostly associated with the side effects of the washout procedure and the temporary device insertion. These are listed below:

Risk of infection

Risk of causing further bleeding into the brain

Drainage tube blockage or dysfunction – If this occurs the participant's doctor will assess if they may need to have another operation to correct this or to insert a permanent VP shunt.

Seizure (seizures are caused by a sudden burst of electrical activity that temporarily affects how it works).

Leakage of fluid surrounding the brain

Electrolyte disturbance

Stroke (less than 1 %): Any procedure carried out on the brain carries a small risk of stroke.

For participants randomised to receive neuroendoscopic lavage (or washout) (Intervention Group), this is a more invasive procedure. It therefore increases the anaesthetic time by about 30 minutes, but this is not thought to be a significant risk. General anaesthetics have some risks and side effects, and the participant's anaesthetist will discuss these with the parent/guardian(s) before surgery.

Risks associated with the neuroendoscopic lavage (or washout) are listed here:

Risk of brain injury (less than 1%): The procedure involves the insertion of a small camera (neuroendoscope) into the fluid spaces of the brain to wash out as much of the blood as possible before inserting the temporary drainage tube. Because the camera (neuroendoscope) has a slightly larger diameter than the catheter used to inset the drainage device, there is the potential to cause damage to the brain at the point where the camera enters the fluid space.

Risk of further bleeding (less than 1 in 10): Washing the blood clot out from the ventricular system may also carry a risk of causing a further bleed within the brain. In a small pilot study the rate of rebleeding was found to be very low, but adding the washout procedure to the normal standard treatment may increase the risk.

Electrolyte disturbance: The use of a washout fluid may cause fluctuations in salt levels in the blood. This also increases the risk of seizure in babies that receive the washout.

Study doctors will be monitoring all participants in the study very carefully. Continuing to assess any risk related to this procedure is an important part of the study.

Where is the study run from?

UCL Comprehensive Clinical Trials Unit (CCTU) (UK)

When is the study starting and how long is it expected to run for?

March 2023 to February 2029

Who is funding the study?

National Institute for Health and Care Research (NIHR) (UK).

Who is the main contact?

1. Chief Scientific Investigator: Kristian Aquilina: [kristian.aquilina@gosh.nhs.uk](mailto:kristian.aquilina@gosh.nhs.uk)

2. Trial Manager: Sue Massingham: [cctu.enlivenuk@ucl.ac.uk](mailto:cctu.enlivenuk@ucl.ac.uk)

# Contact information

## Type(s)

Scientific, Principal investigator

## Contact name

Mr Kristian Aquilina

## Contact details

Consultant paediatric neurosurgeon  
Great Ormond Street Hospital  
Department of Neurosurgery  
Level 10 Old Nurses Home  
Great Ormond Street  
London  
United Kingdom  
WC1N 3JH  
+44 (0)7791613155  
kristian.aquilina@gosh.nhs.uk

## Type(s)

Public

## Contact name

Ms Sue Massingham

## Contact details

Comprehensive Clinical Trials Unit at UCL  
Floor 2, 90 High Holborn  
London  
United Kingdom  
WC1V 6LJ  
+44 (0)20 7679 9351  
cctu.enlivenuk@ucl.ac.uk

# Additional identifiers

## Clinical Trials Information System (CTIS)

Nil known

## Integrated Research Application System (IRAS)

322127

## ClinicalTrials.gov (NCT)

Nil known

## Protocol serial number

CPMS 56647, NIHR151288, IRAS 322127

# Study information

## Scientific Title

Endoscopic lavage after intraventricular haemorrhage in neonates in the UK: a national randomised controlled trial on the efficacy of neuro-endoscopic lavage

## Acronym

ENLIVEN-UK

## Study objectives

It is hypothesised that the addition of Neuroendoscopic Lavage (NEL) will be safe and will improve neurodevelopmental outcomes at 2 years in children with severe Intraventricular Haemorrhage (IVH) and Post-haemorrhagic Ventricular Dilatation (PHVD).

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Approved 14/12/2023, South West - Central Bristol (2 Redman Place, London, E20 1JQ, United Kingdom; 0207 104 8197; centralbristol.rec@hra.nhs.uk), ref: 23/SW/0137

## Study design

Phase III multi-centre assessor-blinded randomized controlled interventional trial, including an internal pilot study

## Primary study design

Interventional

## Study type(s)

Efficacy, Treatment

## Health condition(s) or problem(s) studied

Intraventricular Haemorrhage (IVH) and Post-haemorrhagic Ventricular Dilatation (PHVD) in premature infants born before 37 weeks of gestational age

## Interventions

This is a phase III, multi-centre, randomised, assessor-blinded, controlled trial of NEL with temporising device (intervention Arm A) vs temporising device alone (standard treatment /Control Arm B).

Arm A (Intervention): NEL with the temporising device. NEL will be carried out within the same operative procedure as the insertion of a clinically indicated temporising device. NEL involves the irrigation of the blood and its breakdown products within the ventricular system and is carried out in a controlled procedure, within approximately 30 minutes, under direct vision.

Arm B (Control/Usual Care) - temporising device alone. Infants will undergo the standard surgical procedure to insert either a Ventricular access device (VAD) or Ventriculosubgaleal shunt (VSGS), at the discretion of the treating surgeon, in line with their standard current practice.

Both the intervention (Arm A) and control arm (Arm B) procedures will be performed by paediatric neurosurgeons who have experience in infant neuro-endoscopy. All infants in Arms A and B will be followed up until they reach 2 years corrected age (+/-2 months).

A computer-generated randomisation sequence, using the SealedEnvelope.com system, will be used to assign the participants to one of the two treatment arms using a 1:1 ratio.

## **Intervention Type**

Procedure/Surgery

## **Primary outcome(s)**

Cognitive Quotient (CQ) measured by the Bayley Scales of Infant and Toddler Development Fourth Edition (Bayley IV) at 2 years' corrected age (+/- 2 months)

## **Key secondary outcome(s)**

1. Developmental measures:

1.1. Motor quotient (MQ): Age equivalent motor score of the Bayley IV divided by corrected age at assessment, measured at 2 years' corrected age

1.2. Language quotient (LQ): Age equivalent language score of the Bayley IV divided by corrected age at assessment, measured at 2 years' corrected age

2. Other neurological and functional assessments conducted during the 2-year follow-up visit:

2.1. Presence of seizures during the first 2 years and use of anticonvulsant medication at 2 years

2.2. Presence of cerebral palsy (+ accompanying Gross Motor Function Classification System (GMFCS) grade and deficit distribution map using the Classification of SCPE

2.3. Assessment of hearing and vision (British Association of Perinatal Medicine classification) at 2 years' corrected age

2.4. Parent report at 2 years' corrected age:

2.4.1. Brief Infant Toddler Social Emotional Assessment (BITSEA)

2.4.2. Quantitative Checklist for Autism in Toddlers (Q-CHAT)

3. Mortality up to 2 years corrected age

4. NEL and VP shunt related outcomes:

4.1. Safety of NEL, measured by the number of Adverse Events reported until 2 years' corrected age

4.2. Number and type of further surgical procedures required until 2 years' corrected age

4.3. Requirement for permanent VP shunt insertion at 6 months' corrected age

5. Quality of life and health economic assessments:

5.1. Health-related quality of life (HRQoL) in children measured using the TNO-AZL Preschool Children's Quality of Life (TAPQOL) at 12 months and 2 years' corrected age

5.2. HRQoL in primary caregiver measured using the EuroQoL EQ-5D-5L at baseline, 6 months, 12 months and 2 years' corrected age

5.3. Healthcare resource use costs (CSRI (adapted) children version) at 3, 6, 12, 18 months and 2 years' corrected age

5.4. Subsequent cost-effectiveness analysis and cost-benefit analysis of impact on carers based on responses to the EQ-5D-5L

## **Completion date**

28/02/2029

## **Eligibility**

### **Key inclusion criteria**

1. Premature infants born before 37 weeks of gestational age
2. IVH: Papile Grades II-IV on cranial ultrasound scan
3. PHVD: Ventricular index at or beyond the threshold point of the 97th centile for gestational age plus 4 mm on the Levene chart despite 2 attempted lumbar or ventricular punctures.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Neonate

**Lower age limit**

22 weeks

**Upper age limit**

36.85 weeks

**Sex**

All

**Key exclusion criteria**

1. Infants with coagulopathy (INR > 1.6) or platelet disorders (platelet count under 80,000/mL) that persist on attempted correction. Clinical judgement will be made by the Investigator.
2. Infants deemed too unstable for neurosurgical intervention. This is a clinical judgement made by the responsible neurosurgeon, neonatologist and anaesthetic team.
3. Parents or carers unwilling to provide informed consent.

**Date of first enrolment**

09/05/2024

**Date of final enrolment**

31/08/2026

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Great Ormond Street Hospital for Children**

Great Ormond Street

London

United Kingdom

WC1N 3JH

**Study participating centre**  
**Alder Hey Children's Hospital**  
Eaton Road  
West Derby  
Liverpool  
United Kingdom  
L12 2AP

## Sponsor information

**Organisation**  
University College London

**ROR**  
<https://ror.org/02jx3x895>

## Funder(s)

**Funder type**  
Government

**Funder Name**  
National Institute for Health and Care Research

**Alternative Name(s)**  
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

**Funding Body Type**  
Government organisation

**Funding Body Subtype**  
National government

**Location**  
United Kingdom

## Results and Publications

## Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date

## IPD sharing plan summary

Data sharing statement to be made available at a later date

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>		03/11/2025	04/11/2025	Yes	No